Difference between revisions of "Polatuzumab vedotin (Polivy)"
Jump to navigation
Jump to search
m |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*6/10/2019: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL), not otherwise specified]], after at least two prior therapies. ''(Based on GO29365)'' | *6/10/2019: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL), not otherwise specified]], after at least two prior therapies. ''(Based on GO29365)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1/16/2020: Initial conditional approval | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' DCDS4501A | *'''Code name:''' DCDS4501A | ||
| Line 29: | Line 30: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| − | + | [[Category:EMA approved in 2020]] | |
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
[[Category:Genentech product]] | [[Category:Genentech product]] | ||
Revision as of 02:26, 31 December 2022
General information
Class/mechanism from the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
Route: IV
Extravasation: neutral
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/10/2019: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. (Based on GO29365)
History of changes in EMA indication
- 1/16/2020: Initial conditional approval
Also known as
- Code name: DCDS4501A
- Generic name: polatuzumab vedotin-piiq
- Brand name: Polivy